Sanofi Beats Back Apotex Generic In Uroxatral MDL

Law360, New York (January 14, 2011, 6:58 PM EST) -- A federal judge overseeing the multidistrict litigation arising from Sanofi-Aventis SA’s prostate drug Uroxatral has held that the patent covering the treatment was valid and infringed by Apotex Inc.’s proposed generic copycat.

Judge Gregory Sleet of the U.S. District Court for the District of Delaware on Friday issued the decision, which was based on an earlier ruling in favor of Sanofi in its fight against Mylan Pharmaceuticals Inc. over a generic version of the drug.

Sanofi initiated patent infringement actions against Apotex, Mylan, Aurobindo Pharma Ltd.,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.